Manuel Reyes, MD
Interventional Cardiology · Houston, TXNPI 1891069050
Payments from drug & device makers
Across 828 payments — averaging $106.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$43K
- Edwards Lifesciences$31K
- Cardiovascular Systems Inc.$9K
- Biosense Webster, Inc.$1K
- Medtronic$736
- E.r. Squibb & Sons, L.L.C.$503
- plus $4K from 30 others
What the payments were for
- Consulting fees$44,95051%
- Speaking & faculty fees$14,55016%
- Travel & lodging$5,9987%
- Food & beverage$22,69126%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 503 | $42,520 |
| Edwards Lifesciences | 91 | $30,596 |
| Cardiovascular Systems Inc. | 13 | $9,037 |
| Biosense Webster, Inc. | 65 | $1,275 |
| Medtronic(2 entities) | 15 | $736 |
| E.r. Squibb & Sons, L.L.C. | 27 | $503 |
| Boston Scientific | 8 | $370 |
| GE HealthCare | 3 | $296 |
| Abiomed | 2 | $295 |
| Angiodynamics, Inc. | 3 | $248 |
| Biotronik Inc. | 6 | $235 |
| Novartis | 12 | $199 |
| Pfizer | 9 | $183 |
| Elutia, Inc. | 1 | $167 |
| Johnson & Johnson | 21 | $161 |
| Amgen | 9 | $154 |
| AstraZeneca | 2 | $146 |
| Acutus Medical, Inc. | 1 | $135 |
| Veryan Medical Incorporated | 1 | $132 |
| Heartflow, Inc. | 8 | $124 |
| Reflow Medical Inc | 1 | $116 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Impulse Dynamics (USA) Inc. | 4 | $81 |
| Esperion Therapeutics, Inc. | 4 | $80 |
| Novo Nordisk | 3 | $69 |
| Bardy Diagnostics, Inc. | 1 | $68 |
| G Medical Diagnostic Services, Inc. | 1 | $40 |
| Endologix LLC | 1 | $31 |
| Cardiva Medical, Inc. | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$26,401
- Xience V coronary stent system$12,175
- CardioMEMS HF System$9,289
- Coronary Orbital Atherectomy System$8,550
- DRAGONFLY OPSTAR$6,000
- Peripheral Orbital Atherectomy System$5,400
- HeartMate 3 Left Ventricular Dev$1,500
- TRICLIP$1,006
- CARDIOMEMS$691
- Optis Coronary Imaging System$660
- Omnilink Elite vascular stent system$633
- Xience Sierra Coronary Stent$567
- SAPIEN 3 Ultra RESILIA$409
- Impella$295
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$266
- Assurity Pacemaker$252
- Mitra Clip system$250
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$237
- Diamondback Peripheral$234
- Quadra Assura CRT Defibrillator$180
How this compares
$88,249 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 222 | $245,916 |
| MultaqDronedarone Hcl | 66 | $89,632 |
| Repatha SureclickEvolocumab | 102 | $81,875 |
| XareltoRivaroxaban | 47 | $51,131 |
| Praluent PenAlirocumab | 39 | $34,465 |
| Repatha SyringeEvolocumab | 31 | $28,300 |
| EntrestoSacubitril/Valsartan | 18 | $21,120 |
| Rosuvastatin Calcium | 309 | $5,709 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 180 | $3,029 |
| Carvedilol | 274 | $2,928 |
| Nifedipine ErNifedipine | 100 | $2,913 |
| Metoprolol Succinate | 153 | $2,795 |
| Losartan Potassium | 225 | $2,730 |
| Olmesartan Medoxomil | 88 | $2,306 |
| Amiodarone Hcl | 36 | $2,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $183 | $245,916222 claims |
| Sanofi-aventis U.S. LLCMultaq | $85 | $89,63266 claims |
| Johnson & JohnsonXarelto | $161 | $51,13147 claims |
| NovartisEntresto | $199 | $21,12018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Abhijeet DhobleHouston$2.7M
- John IsaacHouston$1.8M
- Amir KashaniHouston$1.3M
- Biswajit KarHouston$785K
- Michele SartoriHouston$603K
- Guilherme SilvaHouston$516K
- Sachin KumarHouston$446K
- Marwan JumeanHouston$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.